These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1404 related items for PubMed ID: 31982822

  • 1. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B, Liu Y, Zhou S, Jiang H, Zhu K, Wang R.
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [Abstract] [Full Text] [Related]

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V.
    Cochrane Database Syst Rev; 2020 Dec 14; 12(12):CD013257. PubMed ID: 33316104
    [Abstract] [Full Text] [Related]

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V.
    Cochrane Database Syst Rev; 2021 Apr 30; 4(4):CD013257. PubMed ID: 33930176
    [Abstract] [Full Text] [Related]

  • 5. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y, Duan J, Guan Q, Xue P, Zheng Y.
    Int Immunopharmacol; 2020 Jul 30; 84():106452. PubMed ID: 32339922
    [Abstract] [Full Text] [Related]

  • 6. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N.
    Lung Cancer; 2019 Feb 30; 128():113-119. PubMed ID: 30642442
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR, Wu TW.
    Thorac Cancer; 2019 May 30; 10(5):1176-1181. PubMed ID: 30969033
    [Abstract] [Full Text] [Related]

  • 8. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM, Chen SY, Yang B, Wang Y, Han RY, An MN, Dong YL, You HS.
    Cancer Med; 2021 Sep 30; 10(18):6344-6353. PubMed ID: 34382361
    [Abstract] [Full Text] [Related]

  • 9. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L.
    J Immunother Cancer; 2018 Dec 22; 6(1):155. PubMed ID: 30577837
    [Abstract] [Full Text] [Related]

  • 10. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, Akbari K, Granitz M, Hutarew G, Kaiser B, Greil R, Lamprecht B.
    Target Oncol; 2019 Dec 22; 14(6):707-717. PubMed ID: 31654203
    [Abstract] [Full Text] [Related]

  • 11. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, Lu B, Wang X.
    Cancer Med; 2021 Feb 22; 10(4):1222-1239. PubMed ID: 33465302
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K, Horinouchi H, Tanaka M, Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y.
    J Cancer Res Clin Oncol; 2021 Jan 22; 147(1):245-251. PubMed ID: 32705363
    [Abstract] [Full Text] [Related]

  • 13. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ.
    Oncologist; 2019 Jun 22; 24(6):820-828. PubMed ID: 30867242
    [Abstract] [Full Text] [Related]

  • 14. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Kusumoto M, Yamamoto N, Ohe Y.
    Med Oncol; 2019 Apr 27; 36(6):49. PubMed ID: 31030326
    [Abstract] [Full Text] [Related]

  • 15. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH.
    J Cancer Res Clin Oncol; 2021 Aug 27; 147(8):2459-2469. PubMed ID: 33523301
    [Abstract] [Full Text] [Related]

  • 16. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H, Liu L, Peng Q, Chen J, Zhu YD.
    BMC Cancer; 2021 Nov 13; 21(1):1220. PubMed ID: 34774004
    [Abstract] [Full Text] [Related]

  • 17. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J, Gu J.
    Future Oncol; 2019 May 13; 15(14):1667-1678. PubMed ID: 31041879
    [Abstract] [Full Text] [Related]

  • 18. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V.
    Clin Lung Cancer; 2018 May 13; 19(3):e335-e348. PubMed ID: 29433902
    [Abstract] [Full Text] [Related]

  • 19. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y, Chen W, Dong L, Duan L, Gao P.
    Clin Transl Oncol; 2024 Oct 13; 26(10):2488-2502. PubMed ID: 38625495
    [Abstract] [Full Text] [Related]

  • 20. Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.
    Hurkmans DP, Kuipers ME, Smit J, van Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von der Thüsen JH, van der Burg SH.
    Cancer Immunol Immunother; 2020 May 13; 69(5):771-777. PubMed ID: 32047958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.